16 May 2025



## Proteome Sciences plc ("Proteome Sciences" or the "Company")

## **Result of Annual General Meeting (AGM)**

The directors of Proteome Sciences are pleased to announce that at the Company's AGM, held at 12.00 noon today, all resolutions were duly passed.

**Proteome Sciences plc** Christopher Pearce, Executive Chairman Dr. Ian Pike, Chief Scientific Officer Richard Dennis, Chief Commercial Officer

## Allenby Capital Limited (Nominated Adviser & Broker)

John Depasquale / Lauren Wright (Corporate Finance) Tony Quirke / Stefano Aquilino (Equity Sales & Corporate Broking) Tel: +44 (0) 20 3328 5656

Tel: +44 (0)20 7043 2116

## About Proteome Sciences plc. (www.proteomics.com)

Proteome Sciences plc is a specialist provider of contract proteomics services to enable drug discovery, development and biomarker identification, and employs proprietary workflows for the optimum analysis of tissues, cells and body fluids. SysQuant<sup>®</sup> and TMT<sup>®</sup>MS2 are unbiased methods for identifying and contextualising new targets and defining mechanisms of biological activity, while analysis using Super-Depletion and TMTcalibrator<sup>™</sup> provides access to over 8,500 circulating plasma proteins for the discovery of disease-related biomarkers. Targeted assay development using mass spectrometry delivers high sensitivity, interference-free biomarker analyses in situations where standard ELISA assays are not available.